FT. MYERS, FL / ACCESSWIRE / November 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading supplier of oncology sorting out and world contract be taught products and providers, has appointed David B. Perez – a old chief in clinical devices and successfully being care products and providers – to lend a hand on its Board of Directors, effective November 3, 2022.
“I am delighted to welcome David to our Board of Directors. With his proven document in rising and scaling highly-regulated companies, David brings precious skills and insights to NeoGenomics as the corporate continues to lengthen its sorting out and info products and providers to transform cancer care,” talked about Lynn Tetrault, Chair of the Board of NeoGenomics.
With 40 years of world govt management skills, Mr. Perez has led the expansion and operations of several companies, rising and scaling organically by blueprint of be taught & type and innovation as successfully as by blueprint of mergers and acquisitions. In March 2019, he retired from his location as president and CEO of Terumo BCT, an organization dedicated to blood banking, transfusion treatment and cell-primarily based therapies, following a comprehensive two-one year succession and transition thought and now serves as an just board member for public, non-public equity and non-profit organizations.
At some point of his nearly 20-one year tenure, Mr. Perez guided Terumo BCT by blueprint of several foreign possession constructions, leveraging his extensive skills leading advanced, multinational companies and various, corrupt-cultural organizations. Beneath his management, the corporate reworked from a single manufacturing and R&D net web stammer to a multi-nationwide biomedical organization with five R&D centers and six manufacturing vegetation, as he helped power world earnings verbalize from $160 million to $1 billion. Mr. Perez holds a BA in Political Science from Texas Tech University.
“I am inflamed to be half of the NeoGenomics’ Board supporting the mission of the corporate and to fragment my skills and insights as the corporate continues to admire its imaginative and prescient of bringing uncompromising quality, excellent service, and modern solutions to bettering the lives of of us residing with cancer,” Perez talked about. “I delight in watched NeoGenomics evolve into a world chief in cancer diagnostic sorting out and contract be taught products and providers, and I preserve up for being piece of its subsequent chapter.”
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics sorting out and info products and providers, providing considered one of many most comprehensive oncology-centered sorting out menus in the enviornment for physicians to serve them diagnose and address cancer. The Firm’s Pharma Products and providers Division serves pharmaceutical purchasers in clinical trials and drug type.
NeoGenomics is devoted to connecting patients with life altering therapies and trials. We predict about that, collectively, with our companions, we can serve patients with cancer this day and the following person identified day after recently to come. In undertaking these commitments, NeoGenomics adheres to all linked info protection authorized pointers, presents transparency and selection to patients concerning the handling and spend of their info by blueprint of our Glimpse of Privacy Practices, and has invested in leading technologies to be distinct the solutions we preserve is secured at all instances.
Headquartered in Fortress Myers, FL, NeoGenomics operates CAP approved and CLIA licensed laboratories in Fortress Myers and Tampa, Florida; Aliso Viejo and Carlsbad, California; Learn Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP approved laboratories in Rolle, Switzerland; Singapore and China. NeoGenomics serves the wants of pathologists, oncologists, academic centers, clinical institution programs, pharmaceutical companies, constructed-in service offer networks, and managed care organizations sooner or later of the United States, and pharmaceutical companies in Europe and Asia.
Ahead Having a search Statements
This press commence involves ahead-having a search statements. These ahead-having a search statements on the complete could maybe furthermore be identified via phrases corresponding to “stay awake for,” are waiting for,” thought,” “could maybe,” “would,” “could maybe,” “will,” “have in mind,” “estimate,” “forecast,” “goal,” “challenge, “guidance,” “thought,” “doable” and other phrases of an identical that implies, even though now now not all ahead-having a search statements encompass these phrases. These ahead-having a search statements address a bunch of matters, including statements concerning bettering operational effectivity, returning to successful verbalize and its ongoing govt recruitment direction of. Each and every ahead-having a search assertion contained on this press commence is self-discipline to a form of dangers and uncertainties that will net web stammer off accurate results to differ materially from those expressed or implied by such assertion. Acceptable dangers and uncertainties encompass, amongst others, the Firm’s ability to title and enforce appropriate monetary and operational initiatives to serve efficiency, to title and recruit govt candidates, to continue gaining fresh customers, acknowledge to the results of the COVID-19 outbreak, offer fresh sorts of tests, integrate its acquisitions and otherwise enforce its industry thought, and the dangers identified under the heading “Chance Components” in the Firm’s Annual Picture on Enjoy 10-Good ample for the one year ended December 31, 2021 filed with the SEC on February 25, 2022 as successfully as other info previously filed with the SEC.
We warning investors now to now not operate undue reliance on the ahead-having a search statements contained on this press commence. You’ll want to presumably be encouraged to read our filings with the SEC, available in the market at www.sec.gov, for a dialogue of these and other dangers and uncertainties. The ahead-having a search statements on this press commence talk handiest as of the date of this doc (unless yet any other date is indicated), and we undertake no duty to update or revise any of these statements. Our industry is self-discipline to particular dangers and uncertainties, including those referenced above. Merchants, doable investors, and others can delight in to smooth give cautious consideration to these dangers and uncertainties.
For additional info, please contact:
William B. Bonello
Chief Financial Officer
SOURCE: NeoGenomics, Inc.